adelo, a precision health engagement and intelligence company, has acquired Dot I/O Health, a data science-driven pharmaceutical strategy consultancy. As part of the acquisition, Nigel Breakwell, co-founder and Managing Partner of Dot I/O Health, joins adelo as Managing Partner, bringing more than three decades of pharmaceutical strategy, communications, and consulting experience directly inside the platform.
Breakwell began his career at Sanofi and MSD before becoming Joint CEO & Head of Health at Edelman UK.
He subsequently founded the WCG (now Real Chemistry) London office, before establishing Breakwell Healthcare Consulting in 2013 and co-founding Dot I/O Health in 2015.
Breakwell also serves as Chair and Trustee of the Arrhythmia Alliance UK and US and is a published author in patient engagement, migrant population health and cardiac arrhythmias.
Nigel Breakwell, Managing Partner at adelo, said: “My role is to ensure that intelligence connects to genuine pharmaceutical strategy, from global positioning through to the last mile of implementation – because that is precisely where launches are won and lost.”
Ben Randal, Strategy Lead at adelo, added: “Bringing Nigel and the Dot I/O Health team inside adelo means the intelligence we generate now connects directly to the decisions that determine whether a $2.5 billion investment comes home.”